Restoring skeletal remodeling in antiresorptive-treated patients: clinical outcomes of teriparatide in medication-related osteonecrosis of the jaw
Authors' conclusion
Published reports describe frequent clinical improvement after teriparatide use in MRONJ. However, the evidence remains descriptive, heterogeneous, and commonly confounded by concomitant therapies.
Study context
- Population
- Patients with established medication-related osteonecrosis of the jaw (MRONJ) treated with teriparatide, regardless of triggering medication34 publications
- Participants
- 207 patients
- Outcome
- Clinical outcomes (201 patients with data)
Methodological detailsPRISMA 2020, qualitative synthesis
- PRISMA 2020
- Qualitative synthesis
Main finding
As reported in the abstract
Complete coverage/healing
163
Partial improvement
24
No change
12
Worsening
2
Further findings
Patient and treatment characteristics
- Stage 2 disease predominated among stageable cases; mandibular involvement most frequent; daily dosing more common than weekly
- Bisphosphonate exposure predominated, denosumab-associated cases fewer; differential effectiveness by antiresorptive class could not be determined
Safety
Teriparatide discontinuation or dropout after initiation
- Patients with discontinuation or dropout
- 13
Original publication
Restoring skeletal remodeling in antiresorptive-treated patients: clinical outcomes of teriparatide in medication-related osteonecrosis of the jaw. Osteoporos Int. Published 19 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →